Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07827599 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Confirm Efficacy of a Single Dose of Baloxavir Marboxil in the Post-exposure Prophylaxis (PEP) of Influenza Virus Infection in Chinese Participants

Name: A Study to Confirm Efficacy of a Single Dose of Baloxavir Marboxil in the Post-exposure Prophylaxis (PEP) of Influenza Virus Infection in Chinese Participants — clinical trial record (NCT07827599)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: Pearlstone

StatusNot Yet Recruiting

PhasePhase 3

SponsorHoffmann-La Roche

Started2026-09-22

View on ClinicalTrials.gov ↗

Roche/Genentech

364 trials monitored

See 34 trials at risk

The main purpose of the study is to evaluate the efficacy of a single dose of baloxavir marboxil compared with placebo in the PEP of influenza virus infection with respect to symptomatic, laboratory-confirmed influenza in participants who are household contacts (HHCs) of participants with influenza (index participants).

Trial Details

NCT Number	NCT07827599
Lead Sponsor	Hoffmann-La Roche
Conditions	Influenza, Human, Respiratory Tract Infections, Post-exposure Prophylaxis
Enrollment	325 participants
Start Date	2026-09-22
Primary Completion	2027-04-30 (estimated)
Study Completion	2027-04-30 (estimated)
Updated on ClinicalTrials.gov	2026-09-18